The Drug-Induced Respiratory Disease Website

Vedolizumab

Rechallenge can lead to relapse of AE/ILD

When available, likelihood and risk given for specific drug

Publications

Pugliese D, Privitera G, Schepis T, Larosa L, Onali S, Scaldaferri F, Gasbarrini A, Caprioli F, Armuzzi A

Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2022 Jun;20;e1483-e1487 — 2022 Jun — e1483-e1487

Diagnosing DIRD

Drug and radiation history

Drug singularity - Correct identification of the drug

Consistent timing of exposure v. onset of symptoms

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

Careful exlusion of another cause

Remission of symptoms with removal of drug

Recurrence with rechallenge (rarely advisable)

Causality assessment

Diagnosing DIRD

Identify causative drugs

LATEST CHANGELOG

No activity has been recorded yet.

View full changelog